BioNano Genomics Inc Stock Research

Market Summary

USD0.71+0.02

Delayedas of 01 Jun 2023, 11:16 am

2.89%

BNGO Alerts

1 major insider buys recently.

BNGO Stock Price

BNGO RSI Chart

BNGO Valuation

Market Cap

212.3M

Price/Earnings (Trailing)

-1.52

Price/Sales (Trailing)

7.19

EV/EBITDA

-1.64

Price/Free Cashflow

-1.7

BNGO Price/Sales (Trailing)

BNGO Profitability

EBT Margin

-470.15%

Return on Equity

-53.17%

Return on Assets

-43.12%

Free Cashflow Yield

-58.76%

BNGO Fundamentals

BNGO Revenue

Revenue (TTM)

29.5M

Revenue Y/Y

30.18%

Revenue Q/Q

-9.74%

BNGO Earnings

Earnings (TTM)

-139.8M

Earnings Y/Y

-23.94%

Earnings Q/Q

4.02%

Price Action

52 Week Range

0.604.35

(Low)(High)

Last 7 days

3.8%

Last 30 days

3.2%

Last 90 days

-49.1%

Trailing 12 Months

-60.0%

BNGO Financial Health

Current Ratio

4.38

BNGO Investor Care

Shares Dilution (1Y)

5.90%

Diluted EPS (TTM)

-0.47

Peers (Alternatives to BioNano Genomics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	34.2B	6.9B	-15.00%	-9.16%	25.88	4.94	7.53%	9.79%
ILMN	31.1B	4.4B	-2.80%	-17.88%	-7.06	6.99	-4.49%	-677.95%
MTD	30.0B	4.0B	-12.99%	2.78%	33.8	7.59	3.66%	11.80%
PKI	14.9B	3.4B	-15.95%	-22.45%	15.51	4.44	-23.30%	29.82%
WAT	14.8B	3.0B	-15.76%	-23.40%	21.52	5	3.42%	-2.23%
MID-CAP
SMALL-CAP
PACB	3.1B	128.3M	9.46%	119.89%	-9.64	24.1	-1.69%	-82.99%
ADPT	1.0B	184.3M	-5.31%	-11.00%	-5.15	5.45	19.29%	17.33%
QTRX	733.9M	104.4M	55.39%	16.31%	-8.67	7.03	-7.50%	-28.77%
NSTG	278.8M	132.0M	-40.20%	-62.34%	-1.73	2.11	-8.69%	-26.95%
HBIO	235.8M	114.5M	-6.05%	52.73%	-117.1	2.06	-5.10%	69.01%
BNGO	212.3M	29.5M	3.16%	-60.01%	-1.52	7.19	43.94%	-51.20%
CDXS	147.4M	116.2M	-45.43%	-79.31%	-3.08	1.27	-4.78%	-132.67%
PSNL	84.2M	68.7M	-22.41%	-54.55%	-0.74	1.23	-13.98%	-40.40%
CSBR	70.6M	53.7M	7.20%	-29.59%	-22.66	1.32	14.70%	-1523.74%

Financials for BioNano Genomics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	6.2%	29,521,000	27,802,000	25,889,000	23,323,000	20,509,000
S&GA Expenses	6.4%	94,296,000	88,596,000	83,083,000	77,194,000	69,240,000
R&D Expenses	7.0%	52,457,000	49,047,000	44,251,000	38,014,000	30,333,000
EBITDA	-6.4%	-120,793,000	-113,563,000	-104,425,000	-92,727,000	-
EBITDA Margin	1.0%	-4.34	-4.39	-16.21	-4.52	-
Earnings Before Taxes	-5.5%	-137,868,000	-130,712,000	-122,557,000	-111,494,000	-98,154,000
EBT Margin	0.7%	-4.70	-4.73	-17.31	-4.79	-
Interest Expenses	0%	298,000	298,000	251,000	180,000	406,000
Net Income	-5.4%	-139,768,000	-132,596,000	-116,868,000	-105,812,000	-92,440,000
Net Income Margin	-5.7%	-4.77	-4.51	-16.43	-4.51	-
Free Cahsflow	-7.7%	-124,816,000	-115,921,000	-106,430,000	-90,861,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-5.0%	292	308	324	322	348
Current Assets	-9.4%	143	157	218	216	242
Cash Equivalents	-19.5%	4.00	5.00	28.00	27.00	24.00
Inventory	11.3%	33.00	30.00	25.00	21.00	16.00
Net PPE	5.7%	19.00	18.00	16.00	14.00	13.00
Goodwill	0%	77.00	77.00	56.00	56.00	56.00
Liabilities	4.4%	61.00	58.00	42.00	37.00	37.00
Current Liabilities	6.3%	38.00	36.00	34.00	28.00	19.00
Shareholder's Equity	-7.2%	231	249	282	285	311
Retained Earnings	-10.7%	-385	-348	-310	-278	-246
Additional Paid-In Capital	3.1%	618	599	594	565	559
Shares Outstanding	3.2%	307	297	297	290	290

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	0.1%	-124	-124	-115	-106	-90.52
Share Based Compensation	-5.4%	21.00	22.00	22.00	18.00	14.00
Cashflow From Investing	-18.6%	67.00	83.00	-21.35	-214	-246
Cashflow From Financing	64.6%	38.00	23.00	25.00	16.00	-1.42

Risks for BNGO

What is the probability of a big loss on BNGO?

94.8%

Probability that BioNano Genomics stock will be more than 20% underwater in next one year

94.8%

Probability that BioNano Genomics stock will be more than 30% underwater in next one year.

92.7%

Probability that BioNano Genomics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BNGO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BioNano Genomics was unfortunately bought at previous high price.

Drawdowns

Returns for BNGO

Cumulative Returns on BNGO

15.5%

3-Year Cumulative Returns

Which funds bought or sold BNGO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-8.53	-17,120	39,090	-%
2023-05-22	Arete Wealth Advisors, LLC	reduced	-0.94	-54,699,200	41,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	35.2	8,000	265,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-41.28	-150,000	120,000	-%
2023-05-17	Certified Advisory Corp	new	-	17,261	17,261	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-8,000	-	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	135	189,851	429,857	-%
2023-05-16	JANE STREET GROUP, LLC	reduced	-12.53	-86,118	170,950	-%
2023-05-16	CIM INVESTMENT MANAGEMENT INC	added	3.67	-12,963	48,242	0.02%
2023-05-16	Ancora Advisors, LLC	unchanged	-	110	1,110	-%

Latest Funds Activity

Are funds buying BNGO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BNGO

No. of Funds

BNGO Alerts

1 major insider buys recently.

BioNano Genomics News

Schedule 13G FIlings of BioNano Genomics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	5.41%	16,064,444	SC 13G/A
Jan 30, 2023	blackrock inc.	7.8%	23,240,256	SC 13G/A
Feb 09, 2022	vanguard group inc	5.13%	14,825,634	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	18,660,129	SC 13G
Feb 09, 2021	hudson bay capital management lp	1.24%	1,920,000	SC 13G/A
Jan 21, 2021	domain partners viii, l.p.	-	0	SC 13G/A
Feb 14, 2020	sio capital management, llc	4.57%	0	SC 13G/A
Jan 31, 2020	hudson bay capital management lp	7.09%	2,020,000	SC 13G
Nov 13, 2019	innovatus life sciences lending fund i, lp	5.58%	1,218,703	SC 13D/A
Nov 04, 2019	innovatus life sciences lending fund i, lp	3.96%	849,552	SC 13D/A

BNGO Fair Value

Show Fair-Value

Recent SEC filings of BioNano Genomics

View All Filings

Date Filed	Form Type	Document
May 16, 2023	4	Insider Trading
May 16, 2023	4	Insider Trading
May 16, 2023	4	Insider Trading
May 16, 2023	4	Insider Trading
May 10, 2023	EFFECT	EFFECT
May 09, 2023	10-Q	Quarterly Report
May 09, 2023	8-K	Current Report
May 08, 2023	S-3/A	S-3/A
May 01, 2023	DEFA14A	DEFA14A
Apr 28, 2023	DEF 14A	DEF 14A

Latest Insider Trading transactions for BNGO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-16	Holmlin R. Erik	bought	9,639	0.6426	15,000	president and ceo
2023-05-12	Stewart Christopher P.	bought	33,415	0.6683	50,000	chief financial officer
2023-05-12	OLDAKOWSKI MARK	sold (taxes)	-27,387	0.66	-41,496	chief operating officer
2023-05-12	Holmlin R. Erik	sold (taxes)	-33,093	0.66	-50,141	president and ceo
2023-02-15	Stewart Christopher P.	acquired	-	-	105,000	chief financial officer
2023-02-15	Chaubey Alka	acquired	-	-	120,000	chief medical officer
2023-02-15	OLDAKOWSKI MARK	acquired	-	-	120,000	chief operating officer
2023-02-15	Holmlin R. Erik	acquired	-	-	300,000	president and ceo
2022-08-15	Linney Yvonne	acquired	7,600	0.38	20,000	-
2022-08-15	Linney Yvonne	sold	-72,402	3.6201	-20,000	-

About BioNano Genomics

Robert Erik Holmlin, PhD

www.bionanogenomics.com

300

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

BNGO Income Statement

2023-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 7,415	$ 5,696
Operating expenses:
Total cost of revenue	5,345	4,835
Operating expenses:
Research and development	13,937	10,527
Selling, general and administrative	25,976	20,277
Total operating expenses	39,913	30,804
Loss from operations	(37,843)	(29,943)
Other income (expense):
Interest income	704	110
Interest expense	(76)	(77)
Other income (expense)	117	(33)
Total other income (expense)	745	0
Loss before income taxes	(37,098)	(29,943)
Benefit (provision) for income taxes	(26)	(9)
Net loss	$ (37,124)	$ (29,952)
Net loss per share, basic (in dollars per share)	$ (0.12)	$ (0.11)
Net loss per share, diluted (in dollars per share)	$ (0.12)	$ (0.11)
Weighted-average common shares outstanding, basic (in shares)	302,045	284,613
Weighted-average common shares outstanding, diluted (in shares)	302,045	284,613
Product revenue
Revenue:
Total revenue	$ 5,447	$ 4,206
Operating expenses:
Total cost of revenue	3,858	3,576
Service and other revenue
Revenue:
Total revenue	1,968	1,490
Operating expenses:
Total cost of revenue	$ 1,487	$ 1,259

BNGO Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,104	$ 5,091
Investments	91,704	108,095
Accounts receivable, net	6,780	7,022
Inventory	33,113	29,761
Prepaid expenses and other current assets	6,856	7,329
Total current assets	142,557	157,298
Restricted cash	400	400
Property and equipment, net	19,050	18,029
Operating lease right-of-use assets	7,062	7,222
Finance lease right-of-use assets	3,657	3,707
Intangible assets, net	39,351	41,143
Goodwill	77,289	77,289
Other long-term assets	2,785	2,414
Total assets	292,151	307,502
Current liabilities:
Accounts payable	15,780	12,534
Accrued expenses	9,250	10,552
Contract liabilities	1,127	871
Operating lease liability	2,235	2,260
Finance lease liability	282	285
Contingent consideration	9,461	9,382
Total current liabilities	38,135	35,884
Operating lease liability, net of current portion	5,043	5,504
Finance lease liability, net of current portion	3,612	3,619
Contingent consideration, net of current portion	13,680	12,970
Long-term contract liabilities	194	127
Total liabilities	60,664	58,104
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at March 31, 2023 and December 31, 2022; 306,790,000 and 297,183,000 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	31	30
Additional paid-in capital	617,960	599,207
Accumulated deficit	(385,839)	(348,715)
Accumulated other comprehensive loss	(665)	(1,124)
Total stockholders’ equity	231,487	249,398
Total liabilities and stockholders’ equity	$ 292,151	$ 307,502